NewsBenzingaTruist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115 Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115 Benzinga 2026.10.20 15:38 (GMT+0) Open on Benzinga Other news Best Buy Bets Big on Gaming, Launches New Platform Ahead of Holiday Rush JP Morgan Maintains Neutral on Flutter Entertainment, Lowers Price Target to $110 JP Morgan Maintains Overweight on Wynn Resorts, Lowers Price Target to $115 Mastercard Taps Coinbase, Cloudflare as AI Agents Learn to Pay Oppenheimer Downgrades Braze to Perform JP Morgan Maintains Neutral on Sportradar Gr, Lowers Price Target to $13
